Anthropic has released Claude Science, a specialized AI workbench equipped with over 60 curated scientific skills and connectors designed to help medical researchers accelerate drug discovery and development processes. The tool marks a significant expansion of the company's healthcare ambitions, positioning AI as a core component of how researchers design experiments, analyze biological data, and move potential treatments from discovery to patients faster.

What Is Claude Science and How Does It Work?

Claude Science is a standalone product that operates as an "AI workbench for scientists," offering researchers direct access to an AI agent with specialized capabilities spanning multiple life science disciplines. Unlike Anthropic's earlier Claude for Life Sciences, which launched in October 2025 as a suite of plugins and connectors, Claude Science is positioned as a primary tool alongside other flagship Anthropic products like Claude Code and Claude Cowork.

The platform is designed specifically for the unique demands of scientific research. It enables medical researchers, clinical coordinators, and regulatory affairs managers to leverage AI for tasks that traditionally consume weeks or months of manual work. The tool can help researchers design experiments, review scientific literature, analyze biological datasets, and identify patterns that might otherwise remain hidden in large volumes of data.

How Are Pharmaceutical Companies Using AI to Speed Up Medicine Development?

Major pharmaceutical organizations are already reporting measurable efficiency gains from deploying AI tools like Claude Science across their research and development pipelines. These companies are using AI to compress timelines and streamline operations that historically required extensive human coordination and analysis.

• Content Automation: Pharmaceutical firms are automating document and content workflows in medicine development, transforming how research data flows from discovery through regulatory approval.
• Enterprise Deployment: Large-scale implementation across multiple teams is enhancing collaboration and reducing bottlenecks in the drug development process.
• Efficiency Gains Across the Value Chain: AI is delivering measurable improvements not just in research but throughout the entire pipeline from initial discovery to patient delivery.

"We're seeing efficiency gains across the value-chain, while our enterprise deployment has enhanced how teams work. This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster to patients worldwide," said Emmanuel Frenehard, Chief Digital Officer at Sanofi.

Emmanuel Frenehard, Chief Digital Officer at Sanofi

Louise Lind Skov, Director of Content Digitalisation at Novo Nordisk, emphasized that her organization has been an early adopter of automation in pharmaceutical development. She noted that working with Anthropic and Claude has set a new standard for the industry, moving beyond simple task automation to fundamentally transforming how medicines progress from discovery to patients.

"Our work with Anthropic and Claude has set a new standard. We're not just automating tasks, we're transforming how medicines get from discovery to the patients who need them," explained Louise Lind Skov, Director of Content Digitalisation at Novo Nordisk.

Louise Lind Skov, Director of Content Digitalisation at Novo Nordisk

What's Driving the Explosive Growth in AI Healthcare Markets?

The broader healthcare AI market is experiencing rapid expansion driven by multiple converging factors. The global artificial intelligence in healthcare market was valued at USD 36.96 billion in 2025 and is projected to grow to USD 51.20 billion in 2026, eventually reaching approximately USD 744.34 billion by 2035, expanding at a compound annual growth rate of 35.02% from 2026 to 2035.

Generative AI, the category that includes tools like Claude Science, is growing even faster. The global generative AI in healthcare market was valued at USD 2.64 billion in 2025 and is expected to reach USD 3.57 billion in 2026, with projections to hit USD 48.23 billion by 2035, expanding at a compound annual growth rate of 33.71%.

Several key factors are fueling this growth. Rising healthcare costs are pushing organizations to adopt AI tools that can reduce operational expenses and accelerate time-to-market for new treatments. The digitization of patient data through electronic health records (EHRs) is creating the data infrastructure that AI systems need to function effectively. The prevalence of chronic diseases is increasing demand for personalized medicine approaches, which AI can help deliver at scale. Additionally, collaborative efforts between technology providers, healthcare institutions, and research organizations are fostering knowledge exchange and pushing the boundaries of what generative AI can accomplish in medicine.

Why Is Anthropic Building Its Own Biotech Infrastructure?

Claude Science represents more than just a software release for Anthropic. The company is simultaneously building specialized wet labs and strategically acquiring biotech companies to develop practical, hands-on expertise in running scientific programs. This dual approach signals that Anthropic views healthcare and drug discovery not as a software-only opportunity, but as a domain where deep operational knowledge matters.

By combining AI tools with in-house research capabilities, Anthropic is positioning itself to pursue its own research and drug development programs focused on rare and neglected diseases. This strategy allows the company to test and refine Claude Science in real-world research environments while simultaneously contributing to medical challenges that often receive less commercial attention from larger pharmaceutical companies.

What Capabilities Make AI Valuable for Medical Research?

AI technologies bring several distinct advantages to healthcare and research that human researchers alone cannot match at the same speed or scale. AI systems can process and synthesize vast amounts of medical data far more quickly than humans, enabling clinicians and researchers to gain actionable, personalized, and predictive insights in minutes rather than weeks.

Machine learning, a subset of AI, enables systems to learn, adapt, and make inferences by identifying patterns in data. Deep learning, an even more advanced approach, mimics the way the human brain processes information to generate accurate insights and predictions. Natural language processing allows machines to comprehend and generate human language, making it possible for AI to review scientific literature, extract relevant findings, and summarize complex research automatically.

These capabilities are particularly valuable in drug discovery, where researchers must analyze patient medical histories, pathology reports, imaging scans, and experimental results to identify patterns and recommend tailored treatments. What might take a human researcher days or weeks to synthesize, an AI system can accomplish in minutes, freeing researchers to focus on interpretation, validation, and the creative aspects of scientific work.

The startup ecosystem is thriving with innovation in these areas, with intense development activity in machine learning algorithms for medical imaging analysis, natural language processing for clinical documentation, and AI-driven personalized treatment plans. These solutions are increasingly clinically validated and scalable, making them practical for deployment in real healthcare settings.